
|Articles|July 1, 2004
Therapeutic options for sexual dysfunction still growing
Do you think the three available phosphodiesterase type-5 inhibitors-vardenafil hydrochloride (Levitra), tadalafil (Cialis), and sildenafil citrate (Viagra)-are essentially the same, or do they have distinct advantages in the treatment of ED?
Advertisement
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Trial launches of neuromodulation therapy for erectile dysfunction after radical prostatectomy
2
PROSTOX ultra launches on US market following new data presented at ASTRO 2025
3
Andrea B. Apolo, MD, discusses survival gains with EV/pembrolizumab in bladder cancer
4
Rectal diazepam eases instillation of nadofaragene firadenovec in NMIBC
5